Testing a New Drug: Controls, Placebo and the Blind Trial
Controlled trials compare a candidate treatment with an appropriate control. Random allocation and blinding reduce sources of bias, but chance and other limitations still matter. Explain placebo comparisons, participant and researcher blinding, and the stages used to assess a drug's benefits and harms.
What a learner can do afterwards
- Explain what a placebo control rules out and what it does not
- Say why a trial is blinded, and why double-blinding closes a gap that single-blinding leaves open
- Describe the stages a candidate drug passes through before it is prescribed, and what each stage is testing for
1 · Read
A clinical trial studies a treatment in people. A placebo resembles the treatment but lacks the active treatment being tested. When participants do not know their assignments and care is similar, a placebo comparison helps assess effects beyond expectation, natural recovery and study participation. It does not remove every bias or chance difference. The control must be ethical; some trials use an established treatment instead.
Random allocation assigns participants to groups by chance. It reduces systematic differences caused by choosing who gets which treatment and tends to balance other influences. It does not guarantee identical groups, especially in small trials. Researchers compare outcomes and assess whether differences could reflect chance, bias or the treatment.
Here, single-blind means participants do not know their treatment group. This reduces changes in expectations or behaviour caused by knowing assignments; it does not make responses identical. In a double-blind trial, participants and relevant researchers, including those giving care or rating outcomes, do not know assignments. This reduces unequal care and biased ratings. Side effects may reveal assignments, so blinding can fail.
You have seen that an association alone does not establish cause. An observational study measures what people do without assigning treatment. Other differences can explain a link between a pill and recovery. A well-run randomised controlled trial gives stronger causal evidence by assigning treatment and comparing outcomes. Assignment alone is not proof: chance, missing results and bias still matter. An effect can be supported before its full mechanism is known.
Preclinical work uses laboratory tests and, where appropriate, animal studies to examine effects and possible harms. Human trials need independent ethics review and informed consent. Phase 1 mainly studies safety, dose and how the body handles the drug. A small early trial cannot show that a drug is harmless for everyone. Participants must receive clear information about the study and its risks.
Phase 2 studies benefit and dose in people with the condition while checking harms. Phase 3 usually compares benefits and harms in larger groups using an appropriate control. Regulators review evidence before approving routine use; early safety results alone are insufficient. Monitoring continues after approval because uncommon or delayed harms may appear later. Approval does not mean zero risk. Researchers must protect privacy and report results honestly.
Ethical controls, random allocation and blinding reduce bias. Assess chance and limitations too. Further trials, approval review and later monitoring examine benefits and harms.
Lesson, questions and flashcards written for this dataset. OpenStax and Khan Academy informed factual background and question design.
Readings and flashcards written for this dataset, with factual background from OpenStax and Khan Academy.
More to read
What a control group contributes
People can improve during a trial for reasons other than the tested drug. A condition may improve naturally. Expectations, study care and changes in reporting can also affect measured outcomes. A control group gives researchers a comparison.
A placebo resembles the treatment while lacking the active treatment being tested. When assignments are hidden from participants and care is similar, the comparison helps assess the drug's added effect. It does not remove chance or every source of bias. The choice of control must be ethical. Necessary effective care must not be withheld merely to make a comparison easier; some trials use an established treatment instead.
Watching treatment use or assigning it
A survey can ask people which treatments they already use and compare their outcomes. Users and non-users may differ in other ways, so a link between treatment and improvement can have another explanation.
A controlled experiment assigns treatments. Random allocation reduces systematic differences caused by choosing participants for particular groups and tends to balance other influences. It does not guarantee identical groups. A suitable control and careful follow-up strengthen the comparison, but chance, missing results and biased measurements still matter. A well-run trial can support a causal effect before the full biological mechanism is understood.
Why promising drugs need more testing
The amount of a drug given is not always the amount of unchanged drug reaching the bloodstream. Absorption and metabolism can affect that amount, and responses can differ between people. Trials therefore study dose as well as benefits and harms.
Preclinical work examines effects before human trials. Phase 1 mainly studies safety, dose and how the body handles the drug. Phase 2 investigates benefit and dose in people with the condition while checking harms. Phase 3 usually makes comparisons in larger groups. Regulators review evidence before approving routine use. Monitoring continues afterwards because uncommon or delayed harms may appear later. Early success does not guarantee approval or zero risk.
Who knows the treatment assignment?
Blinding hides treatment assignments from specified people. Participant blinding reduces changes in expectations or behaviour caused by knowing the group. It does not force everyone to respond alike.
Researchers' knowledge can affect care and outcome ratings too. Blinding the relevant researchers reduces these influences. A recognisable side effect may reveal an assignment, so researchers need to consider whether assignments stayed hidden.
Blinding cannot prevent deliberate fabrication or every error. Human trials still need independent ethics review and informed consent. Participants need clear information about the study and its risks. Researchers must protect privacy and report results honestly, including disappointing results.
2 · Watch
En anglaisTake it off screen
Where it sits
Optional connections
This opens up
Nothing builds on it yet.
Where this leads
8 questions wait behind this lesson, each with its answer explained. Every answer feeds the sky: stars light as they are learned, and dim when it is time to come back.